Article

Efficacy and Toxicity of Neoadjuvant Chemotherapy versus Chemo-immunotherapy in Triple-Negative Breast Cancer Patients with and without Germline BRCA Mutations

2026-02-13

Abstract excerpt

<title>Abstract</title> <p>Background The addition of pembrolizumab (KN522) to neoadjuvant doxorubicin, cyclophosphamide (AC), carboplatin and paclitaxel (TC) has significantly improved survival, albeit with increased toxicity. This study aims to evaluate the effectiveness and toxicity of KN522 and to examine whether treatment outcomes differ in patients with germline BRCA mutations (gBRCAmut). Methods A retros...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f001f5de-06cb-5863-a9b8-5df8cb416c35
DOI: 10.21203/rs.3.rs-8583057/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Efficacy and Toxicity of Neoadjuvant Chemotherapy versus Chemo-immunotherapy in Triple-Negative Breast Cancer Patients with and without Germline BRCA MutationsDOI 10.21203/rs.3.rs-8583057/v1Read

BRCA1/2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter AnalysisSemantic proximity Read

How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategiesSemantic proximity Read

Therapeutic Advances and New Directions for Triple-Negative Breast CancerSemantic proximity Read

Biology and Management of Patients With Triple-Negative Breast CancerSemantic proximity Read

BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients.Semantic proximity Read

A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer.Semantic proximity Read

Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer.Semantic proximity Read

Targeted Therapies for Triple-Negative Breast Cancer.Semantic proximity Read

Advances in the systemic treatment of triple-negative breast cancer.Semantic proximity Read

Triple-negative breast cancer: unique biology and its management.Semantic proximity Read

Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.Semantic proximity Read

Biomarker Guided Chemotherapy and Immunotherapy Response in Asian Triple-Negative Breast Cancer: A Systematic ReviewSemantic proximity Read